PNPLA3常见变异与多族裔生物样本库中NAFLD诊断年龄相关
研究利用自然语言处理算法从多族裔生物样本库的电子健康记录中定义NAFLD病例1703例和对照8119例,分析PNPLA3 rs738409与NAFLD诊断年龄的关系。结果显示G风险等位基因与更早的NAFLD诊断年龄相关,在西班牙裔中效应最强(HR 1.33),且与NAFLD风险增加相关(OR 1.61)。结论提示可利用该变异在西班牙裔等高危人群中进行风险分层,早期识别受益于预防和治疗策略的患者。
要点
- PNPLA3 rs738409 G等位基因与更早的NAFLD诊断年龄相关,西班牙裔中效应最强。
- 该变异与NAFLD风险增加相关,西班牙裔中OR为1.43。
- PheWAS显示该变异还与其他肝病诊断及更早诊断年龄相关。
核心结论
- PNPLA3 rs738409与更早的NAFLD诊断年龄相关,尤其在西班牙裔中效应显著,提示可用于高危人群风险分层和早期预防。
研究设计与样本
- 对多族裔生物样本库中超过27000名有遗传数据的个体应用自然语言处理算法分析电子健康记录,定义NAFLD病例1703例和对照8119例。
- 进行了生存分析、受试者工作特征分析和全表型关联研究(PheWAS,涵盖10095个电子健康记录衍生诊断)。
主要发现
- PNPLA3 G风险等位基因与更早的NAFLD诊断年龄相关,西班牙裔中风险等位基因携带者诊断可能性比非携带者高15%(HR 1.33;95%CI 1.15-1.53;p<0.0001)。
- 该变异与NAFLD风险增加相关(OR 1.61;95%CI 1.349-1.73;p<0.0001),西班牙裔中效应最强(OR 1.43;95%CI 1.28-1.59;p<0.0001)。
- PheWAS显示该风险变异还与其他肝病诊断及更早诊断年龄相关(p<4.95×10^-6)。
临床怎么用
- 可考虑对西班牙裔等肝病高风险人群中的PNPLA3 rs738409携带者进行风险分层,以早期识别适合早期预防和治疗策略的NAFLD患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The Ile138Met variant (rs738409) in the PNPLA3 gene has the largest effect on non-alcoholic fatty liver disease (NAFLD), increasing the risk of progression to severe forms of liver disease. It remains unknown if the variant plays a role in age of NAFLD onset. We aimed to determine if rs738409 impacts on the age of NAFLD diagnosis. METHODS: We applied a novel natural language processing (NLP) algorithm to a longitudinal electronic health records (EHR) dataset of >27,000 individuals with genetic data from a multi-ethnic biobank, defining NAFLD cases (n = 1,703) and confirming controls (n = 8,119). We conducted i) a survival analysis to determine if age at diagnosis differed by rs738409 genotype, ii) a receiver operating characteristics analysis to assess the utility of the rs738409 genotype in discriminating NAFLD cases from controls, and iii) a phenome-wide association study (PheWAS) between rs738409 and 10,095 EHR-derived disease diagnoses. RESULTS: The PNPLA3 G risk allele was associated with: i) earlier age of NAFLD diagnosis, with the strongest effect in Hispanics (hazard ratio 1.33; 95% CI 1.15-1.53; p <0.0001) among whom a NAFLD diagnosis was 15% more likely in risk allele carriers vs. non-carriers; ii) increased NAFLD risk (odds ratio 1.61; 95% CI 1.349-1.73; p <0.0001), with the strongest effect among Hispanics (odds ratio 1.43; 95% CI 1.28-1.59; p <0.0001); iii) additional liver diseases in a PheWAS (p <4.95 × 10-6) where the risk variant also associated with earlier age of diagnosis. CONCLUSION: Given the role of the rs738409 in NAFLD diagnosis age, our results suggest that stratifying risk within populations known to have an enhanced risk of liver disease, such as Hispanic carriers of the rs738409 variant, would be effective in earlier identification of those who would benefit most from early NAFLD prevention and treatment strategies. LAY SUMMARY: Despite clear associations between the PNPLA3 rs738409 variant and elevated risk of progression from non-alcoholic fatty liver disease (NAFLD) to more severe forms of liver disease, it remains unknown if PNPLA3 rs738409 plays a role in the age of NAFLD onset. Herein, we found that this risk variant is associated with an earlier age of NAFLD and other liver disease diagnoses; an observation most pronounced in Hispanic Americans. We conclude that PNPLA3 rs738409 could be used to better understand liver disease risk within vulnerable populations and identify patients that may benefit from early prevention strategies.
引用
- Walker RW, Belbin GM, Sorokin EP, et al. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. J Hepatol. 2020. PMID: 32145261. doi:10.1016/j.jhep.2020.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。